Clinical Trial

Survival and Recurrence After ABO-Incompatible Living Donor Liver Transplantation for Hepatocellular Carcinoma

Study acronym: HCC
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This retrospective cohort study aimed to evaluate long-term oncologic outcomes after ABO-incompatible living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC). Patients who underwent LDLT between January 2012 and December 2023 at a single tertiary center were included. Outcomes of interest included overall survival and recurrence patterns, with a focus on differences in time to recurrence between ABO-compatible and ABO-incompatible recipients.
Trial Details
NCT Number NCT07703735
Lead Sponsor Seoung Hoon Kim
Conditions Liver Transplantation, Hepatocellular Carcinoma (HCC)
Enrollment 371 participants
Start Date 2012-01-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-14